Oncotype DX is a genetic test that helps to predict the likelihood of breast cancer recurrence in women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. The test analyses the activity of 21 genes in a patient’s tumour tissue sample to provide a Recurrence Score, which ranges from 0 to 100. The higher the score, the greater the likelihood of cancer recurrence.

Oncotype DX can be used to guide treatment decisions for early-stage breast cancer. For example, women with a low Recurrence Score may be candidates for less aggressive treatment, such as breast-conserving surgery and radiatherapy only, and avoid chemotherapy. Women with a high Recurrence Score may benefit from chemotherapy.

The test is now widely used in clinical practice and is NICE approved. It has been widely studied and validated in multiple clinical trials..

In summary, Oncotype DX is a genetic test that can help predict the likelihood of breast cancer recurrence in women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It can be used to guide treatment decisions, and potentially spare some women from unnecessary chemotherapy. It is an important tool for personalising breast cancer treatment and improving patient outcomes.

To discuss Oncotype DX further, feel free to contact us.